We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

CCOI:NASDAQCogent Communications Holdings, Inc. Analysis

Data as of 2026-05-27 - not real-time

$21.62

Latest Price

8/10Risk

Risk Level: High

Executive Summary

Cogent Communications is trading at $21.62, just below the calculated resistance of $24.23 and above the support level of $14.82, with the 20‑day SMA ($18.25) sitting under price while the 50‑day SMA ($19.80) remains below, indicating a narrow upside window. The RSI of 61.7 suggests modest momentum, yet the overall trend is classified as bearish and volume is on a decreasing trajectory, underscoring waning buying pressure. Technicals show a bullish MACD histogram (+0.51) despite a negative MACD line, hinting at a potential short‑term bounce that may be constrained by the broader downtrend. Volatility is extreme at 120% over the past 30 days and beta is elevated (≈1.7), amplifying price swings and risk of further drawdowns, as reflected in a historic max drawdown of over 70%.
Fundamentally, the company reports negative EPS (-$3.54 trailing, -$2.95 forward) and operating margins in the negative (-7.5%), with a profit margin of -19%, indicating earnings pressure. Cash flow is weak, with operating cash flow and free cash flow both negative, and debt levels exceed $2.6 B, raising solvency concerns despite a modest market cap of ~$1.1 B. The dividend yield appears attractive at 5.38% but the payout ratio is absurdly high (>560%), rendering the dividend unsustainable. Recent news adds uncertainty: a JP Morgan upgrade is offset by multiple securities‑fraud investigations, and Q1 sales missed expectations, contributing to mixed sentiment.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Bearish technical trend with decreasing volume
  • Legal investigations creating uncertainty
  • Unsustainable dividend payout

Medium Term

1–3 years
Positive
Model confidence: 6/10

Key Factors

  • Cost‑reduction initiatives improving EBITDA
  • Potential upside if price breaks above resistance
  • JP Morgan upgrade adding analyst support

Long Term

> 3 years
Cautious
Model confidence: 7/10

Key Factors

  • Persistent negative earnings and cash flow
  • High debt load relative to cash
  • Ongoing regulatory and litigation risk

Key Metrics & Analysis

Financial Health

Revenue Growth-3.20%
Profit Margin-19.08%
P/E Ratio-7.3
ROE-877.28%
ROA-1.62%
P/B Ratio-9.9
Op. Cash Flow$-32096000
Free Cash Flow$-108703000
Industry P/E17.1

Technical Analysis

TrendBearish
RSI61.7
Support$14.82
Resistance$24.23
MA 20$18.25
MA 50$19.80
MA 200$26.78
MACDBullish
VolumeDecreasing
Fear & Greed Index92.34

Valuation

Target Price$21.27
Upside/Downside-1.61%
GradeOvervalued
TypeValue
Dividend Yield5.38%

Risk Assessment

Beta1.69
Volatility120.80%
Sector RiskMedium
Reg. RiskHigh
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.